<DOC>
	<DOCNO>NCT00945867</DOCNO>
	<brief_summary>The determination 2D6 genotype enable u determine way flecainide metabolize liver . Some individual poor metabolizers individual extensive metabolizers drug . This also determine patient benefit drug .</brief_summary>
	<brief_title>Cytochrome P450 2D6 ( CYP 450 2D6 ) Genotype Flecainide Efficacy</brief_title>
	<detailed_description>Pharmacogenetics study genetic variation drug metabolize enzyme transporter . Pharmacogenetics one first clinical application Human Genome Project . Pharmacogenomics study role interindividual genomics variability drug response , efficacy , metabolism . It correlate effect entire express genome clinical usefulness toxicity drug . Pharmacogenomics potential change way patient ' therapy optimize , allow era `` personalized medicine '' patient divide group base genetic marker treatment outcome .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Flecainide</mesh_term>
	<criteria>Patients recurrent AF Patients structurally normal heart Patients &gt; 18 YO Patients sign informed consent Renal failure creatinine clearance le 40 Elevated liver enzymes 3 time normal range , cause coagulation test abnormality Pregnant patient Patients treat psychiatric agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>flecainide</keyword>
	<keyword>pharmacogenetics</keyword>
</DOC>